Investigation of UDP-glucuronosyltransferases (UGTs) inhibitory properties of carvacrol

Phytotherapy Research

Volumn 26, Issue 1, 2012, Pages 86-90

  Dong, Rui Hua ^a   Fang, Zhong Ze ^b,c   Zhu, Liang Liang ^b,c   Liang, Si Cheng ^b   Ge, Guang Bo ^b   Yang, Ling ^b   Liu, Ze Yuan ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

carvacrol; drug drug interactions (DDIs); UDP glucuronosyltransferases (UGTs)

Indexed keywords

CARVACROL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A9; HYMECROMONE; PROPOFOL;

ARTICLE; COMPETITIVE INHIBITION; DRUG GLUCURONIDATION; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; INHIBITION KINETICS; LIVER MICROSOME;

GLUCURONOSYLTRANSFERASE; HERB-DRUG INTERACTIONS; HUMANS; HYMECROMONE; ISOENZYMES; KINETICS; MONOTERPENES; PLANT EXTRACTS; RECOMBINANT PROTEINS;

EID: 84855684309     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3525     Document Type: Article

References (25)

1. Austgulen LT, Solheim E, Scheline RR,. 1987. Metabolism in rats of p-cymene derivatives: carvacrol and thymol. Pharmacol Toxicol 61: 98-102. (Pubitemid 17136709)
2. Bjornsson TD, Callaghan JT, Einolf HJ, et al,. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31: 815-832. (Pubitemid 36759050)
3. Chami F, Chami N, Bennis S, Trouillas J, Remmal A,. 2004. Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model. J Antimicrob Chemother 54: 909-914. (Pubitemid 39529986)
4. Evans WE, Relling MV,. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491.
5. Fabian D, Sabol M, Domaracka K, Bujnakova D,. 2006. Essential oils-their antimicrobial activity against Escherichia coli and effect on intestinal cell viability. Toxicol Vitro 20: 1435-1445.
6. Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L,. 2010. Time-dependent inhibition of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 69: 193-199.
7. Hao M, Zhao Y, Chen P, et al,. 2008. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PloS One 3: 1-10.
8. Huang T, Fang ZZ, Yang L,. 2010. Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-glucurosyltransferase (UGT) 2B7 might induce drug-drug interactions. Pharmazie 65: 919-921.
9. Kiang TKL, Ensom MHH, Chang TKH,. 2005. UDP-glucurosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106: 97-132.
10. Kristinsson KG, Magnusdottir AB, Petersen H, Hermansson A,. 2005. Effective treatment of experimental acute otitis media by application of volatile fluids into the ear canal. J Infect Dis 191: 1876-1880. (Pubitemid 40705395)
11. Liang SC, Ge GB, Liu HX, et al,. 2011. Determination of propofol UDP-glucuronosyltransferase (UGT) activities in hepatic microsomes from different species by UFLC-ESI-MS. J Pharm Biomed Anal 54: 236-241.
12. Lin JH, Lu AYH,. 1997. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49: 403-449. (Pubitemid 28030947)
13. Liu Y, Ramirez J, House L, Ratain MJ,. 2010. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 38: 32-39.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ,. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
15. Michalets EL,. 1998. Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 18: 84-112. (Pubitemid 28059007)
16. Radominska-Pandya A, Bratton S, Little JM,. 2005. A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years. Curr Drug Metab 6: 141-160. (Pubitemid 40394342)
17. Ritter JK,. 2000. Roles of glucuronidation and UDP- glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129: 171-193. (Pubitemid 32061059)
18. Smith PA, Sorich MJ, McKinnon RA, Miners JO,. 2003. Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem 46: 1617-1626. (Pubitemid 36444215)
19. Stammati A, Bonsi P, Zucco F, Moezelaar R, Alakomi HL, vonWright A,. 1999. Toxicity of selected plant volatiles in microbial and mammalian short-term assays. Food Chem Toxicol 37: 813-823. (Pubitemid 29472432)
20. Stresser DM, Blanchard AP, Turner SD, et al,. 2000. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28: 1440-1448.
21. Sun DX, Fang ZZ, Zhang YY, Cao YF, Yang L, Yin J,. 2010. Inhibitory effects of curcumenol on human liver cytochrome P450 enzymes. Phytother Res 24: 1213-1216.
22. Tanaka E,. 1998. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 23: 403-416. (Pubitemid 29060690)
23. Tukey RH, Strassburg CP,. 2000. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40: 581-616. (Pubitemid 30340694)
24. Veldhuizen EJA, Tjeerdsma-van bokhaven JLM, Zweijtzer C, Burt SA, Haagsman HP,. 2006. Structural requirements for the antimicrobial activity of carvacrol. J Agric Food Chem 54: 1874-1879.
25. Walter BM, Bilkei G,. 2004. Immunostimulatory effect of dietary oregano etheric oils on lymphocytes from growth-retarded, low-weight growing-finishing pigs and productivity. Tijdschrift voor diergeneeskundeunde 129: 178-181. (Pubitemid 38609950)